Disruptions in Liver Function among Cancer Patients and Patients Treated with Tyrosine Kinase Inhibiting Drugs: Comparisons of Two Population-Based Databases

Table 1

Baseline demographics for ineligible patients and eligible patients: EMR database.

	Cancer cohort					TKI cohort
	Ineligible patients*		Eligible patients**			Ineligible patients*		Eligible patients**
	(𝑁 = 27,488)		(𝑁 = 11,452)		𝑃 value	(𝑁=838)		(𝑁=537)		𝑃 value
	𝑁	%	𝑁	%		𝑁	%	𝑁	%
Gender
Male	9,855	35.9	3,885	33.9	0.0003	418	49.9	254	47.3	0.35
Female	17,633	64.1	7,567	66.1		420	50.1	283	52.7
Age at diagnosis or start of TKI, years (mean (SD))
	62.2 (13.28)		62.4 (13.21)		0.46	62.2 (14.04)		62.6 (14.30)		0.67
Health insurance type
Private	6,613	24.1	1,706	14.9	<0.0001	174	20.8	108	20.1	0.26
Public	3,404	12.4	1,301	11.4		115	13.7	81	15.1
Self	177	0.6	19	0.2		6	0.7	3	0.6
Mixed	7,089	25.8	2,345	20.5		235	28.0	175	32.6
Other/unknown	10,205	37.1	6,081	53.1		308	36.8	170	31.7
Cancer type
Breast	9,964	36.2	3,973	34.7	<0.0001	—	—	—	—
Cervical	474	1.7	130	1.1		—	—	—	—
Colorectal	4,019	14.6	2,054	17.9		—	—	—	—
Connective and other soft tissue	573	2.1	159	1.4		—	—	—	—
Head and neck	872	3.2	352	3.1		—	—	—	—
Gastric	407	1.5	165	1.4		—	—	—	—
Lung	6,306	22.9	3,152	27.5		—	—	—	—
Melanoma	950	3.5	260	2.3		—	—	—	—
Ovarian	980	3.6	460	4.0		—	—	—	—
Prostate	2,308	8.4	504	4.4		—	—	—	—
Renal	635	2.3	243	2.1		—	—	—	—
TKI type
Dasatinib	—	—	—	—		19	2.3	9	1.7	0.088
Erlotinib	—	—	—	—		435	51.9	296	55.1
Gefitinib	—	—	—	—		76	9.1	60	11.2
Imatinib	—	—	—	—		289	34.5	168	31.3
Lapatinib	—	—	—	—		16	1.9	2	0.4
Nilotinib	—	—	—	—		3	0.4	2	0.4
Follow-up time (months); mean (SD)			21 (19)					11 (12)

∗Ineligible patients did not meet the eligibility requirements for the cohort (see Figures 1 and  2). **Eligible patients had to have a normal baseline LFT value taken ≤30 days of index date and one follow-up LFT after index date. SD: standard deviation; TKI: tyrosine kinase inhibitor.